Negative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravis

Página do item simplificado
dc.creatorNayara Felicidade Tomazbraz
dc.creatorNatalia Pessoa Rocha
dc.creatorÉrica Leandro Marciano Vieira
dc.creatorRodrigo Santiago Gomez
dc.creatorIzabela Guimarães Barbosa
dc.creatorOlívio Brito Malheiro
dc.creatorAdriana Maria Kakehasi
dc.creatorAntonio Lucio Teixeira
dc.date.accessioned2023-07-14T23:08:23Z
dc.date.accessioned2025-09-09T01:06:12Z
dc.date.available2023-07-14T23:08:23Z
dc.date.issued2017-05-09
dc.format.mimetypepdf
dc.identifier.doi10.1007/s10072-017-2964-z
dc.identifier.issn15901874
dc.identifier.urihttps://hdl.handle.net/1843/56342
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofNeurological Sciences
dc.rightsAcesso Restrito
dc.subjectMiastenia Gravis
dc.subjectDensidade Óssea
dc.subjectOsteporose
dc.subjectAbsorciometria de Fóton
dc.subject.otherMyasthenia gravis
dc.subject.otherBone mineral density
dc.subject.otherBone metabolism markers
dc.subject.otherOsteoporosis
dc.subject.otherDual-energy X-ray absorptiometry
dc.titleNegative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravis
dc.typeArtigo de periódico
local.citation.epage1413
local.citation.spage1405
local.citation.volume38
local.description.resumoAbstract This current study aimed to evaluate the frequency of low bone mass, osteopenia, and osteoporosis in patients with myasthenia gravis (MG) and to investigate the possible association between bone mineral density (BMD) and plasma levels of bone metabolism markers. Eighty patients with MG and 62 controls BMD were measured in the right femoral neck and lumbar spine by dual-energy X-ray absorptiometry. Plasma concentrations of osteocalcin, osteopontin, osteopro tegerin, tumor necrosis factor (TNF-α), interleukin (IL)-1β, IL-6, dickkopf (DKK-1), sclerostin, insulin, leptin, adrenocorticotropic hormone, parathyroid hormone, and fibroblast growth factor (FGF-23) were analyzed by Luminex®. The mean age of patients was 41.9 years, with 13.5 years of length of illness, and a mean cumulative dose of glucocorticoids 38,123 mg. Patients had significant reduction in BMD of the lumbar, the femoral neck, and in the whole body when compared with controls. Fourteen percent MG patients had osteoporosis at the lumbar spine and 2.5% at the femoral neck. In comparison with controls, patients with MG presented lower levels of osteocalcin, adrenocorticotropic hormone, parathyroid hormone, sclerostin, TNF-α, and DKK-1 and higher levels of FGF-23, leptin, and IL-6. There was a significant negative correlation between cumulative glucocorticoid dose and serum calcium, lumbar spine T-score, femoral neck BMD,T-score, and Z-score. After multivariate analysis, higher TNF-α levels increased the likelihood of presenting low bone mass by 2.62. MG patients under corticotherapy presented low BMD and altered levels of bone markers.
local.publisher.countryBrasil
local.publisher.departmentMED - DEPARTAMENTO DE APARELHO LOCOMOTOR
local.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICA
local.publisher.departmentMED - DEPARTAMENTO DE SAÚDE MENTAL
local.publisher.initialsUFMG
local.url.externahttps://link.springer.com/article/10.1007/s10072-017-2964-z

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG